Benedictine Living Community Medicare and Medicaid Location: 1907 Klein Street, St Peter, Minnesota 56082 Ratings: Phone: (507) 934-2203 |
News Archive
Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
Anchor Therapeutics today announced an initial closing of $10 million in a Series B financing. The investment is being led by current investors TVM Capital, HealthCare Ventures and the Novartis Option Fund. The company is in continuing discussions with additional investors interested in joining the Series B. Anchor Therapeutics is focused on developing peptide drug candidates, called pepducins, that modulate G protein coupled receptors (GPCRs), particularly those historically difficult to target using standard pharmaceutical approaches.
The book, written and supported by international leaders in mental health and women's issues, provides the first comprehensive overview on this crisis, examining the links between violence against women and mental health and the underlying causes, as well as the implications of these findings for mental health policies and programs.
› Verified 4 days ago